Ideally, biological markers of an individual breast cancer will provide information about (1) prognosis for the patient, (2) the best first-line therapy, (3) response to that therapy, (4) early relapse, (5) targets for new therapies and (6) the biology of breast cancer. No single marker could provide all this information and, in any case, the heterogeneous nature of individual breast cancers makes it unlikely that a single marker could reflect the overall potential of the tumour. This suggests that we should look for groups of markers but so many possible markers have been described over the past 20 years that selection of the best combination of markers will be difficult.
The best established marker in breast cancer is the oestrogen receptor (ER). Its role in prognosis and in predicting response to both adjuvant therapy and therapy for advanced disease has been well described (Elledge and Osborne, 1997; Leake, 1997; EBTG, 1998) . Successful quality assurance (QA) exists for the biochemical assay (Romain et al, 1995) and a similar QA scheme is being established for the immunohistochemistry (Barnes et al, 1998) of ER. Largely because of this solid background, a recent study in the UK by Mander et al (1998) showed that only 12.5% of breast cancer units 'do not believe ER status to be important in the management of primary breast cancer' and ER is routinely measured in over 84% of breast disease specialist centres. The authors conclude that failure to measure informative biological markers can 'contribute to differences in outcome between units'. Thus, we have an informative marker, which is both relatively cheap and easy to measure, has a well established QA scheme and is very well defined from studies on large numbers of patients (Romain et al, 1995) . However, it has taken 25 years to get routine ER measurement established. If there is a valid case for the use of other markers, as we believe, then we hope that it will not take so long for them to reach routine use! There is a wide range of potential markers, including oncogene products such as erbB-2, anti-oncogene products such as p53, markers of apoptosis/entry into S phase such as bcl-2, markers of cell growth such as Ki-67 and markers of invasion/early relapse such as the urokinase family, whose potential roles have been regularly reported (see Dowsett (1998) for review and Schmitt et al (1997) for details of the potential of the urokinase family). The problem is to select those combinations of biological markers which provide most information for appropriate sub-groups of patients. However, these combinations of markers will only be established in sound manner if each appropriate clinical trial includes a biomarkers component. All protocols proposed through the EORTC are now checked for the presence or possible insertion of such biological end points. Any biomarker study must, of course, obey established rules on tissue handling, assay procedures and data analysis. Appropriate external QA must be included for all multi-centre assays. Hayes et al (1996) have provided one framework to evaluate the clinical utility of such markers.
New technologies such as reverse transcription polymerase chain reaction on fine-needle aspirates, or DNA microarrays make it much more realistic to work on the small quantities of tissue now available. If the result of the application to patient management of specific packages of biomarkers is to improve therapy selection, reduce overtreatment and increase the quality of life, then such an approach will be a cost-effective development.
Is there any evidence that biological markers could act in such a useful manner? Stal et al (1995) carried out a retrospective study of two biomarkers (erbB-2 and S Phase Fraction) in patients who had been randomized to receive either radiotherapy or CMF. Patients with high S Phase but low erbB-2 responded well to chemotherapy and had a much longer disease-free interval than those treated with radiotherapy, whereas patients with high erbB-2 but low S Phase did much better after radiotherapy than after chemotherapy. These results suggest that biological markers can make a difference. Several other retrospective studies will be published shortly. The outcome of prospective studies is eagerly awaited!
